Sclerostin and Vascular Pathophysiology

被引:55
作者
Catalano, Antonino [1 ,2 ]
Bellone, Federica [1 ,2 ]
Morabito, Nunziata [1 ,2 ]
Corica, Francesco [1 ,2 ]
机构
[1] Univ Messina, Dept Clin & Expt Med, I-98125 Messina, Italy
[2] AOU Policlin G Martino, Via Consolare Valeria, I-98125 Messina, Italy
关键词
sclerostin; Wnt; cardiovascular; atherosclerosis; aging; calcification; chronic kidney disease; diabetes mellitus; WNT SIGNALING PATHWAY; BONE-MINERAL DENSITY; SERUM SCLEROSTIN; POSTMENOPAUSAL WOMEN; ARTERIAL STIFFNESS; CIRCULATING SCLEROSTIN; CARDIOVASCULAR-DISEASE; ATHEROSCLEROTIC PLAQUE; CELL-PROLIFERATION; CALCIFICATION;
D O I
10.3390/ijms21134779
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening. Moreover, it interferes with inflammation processes, monocyte adhesion and migration, as well as with foam cell formation and vascular calcification progression. Sclerostin is a negative regulator of the canonical Wnt signaling pathway and, accordingly, the consequence of increased sclerostin availability can be disruption of the Wnt signalling cascade. Sclerostin is becoming a marker for clinical and subclinical vascular diseases and several lines of evidence illustrate its role in the pathophysiology of the vascular system. Sclerostin levels increase with aging and persist higher in some diseases (e.g., diabetes, chronic kidney disease) that are known to precipitate atherosclerosis and enhance cardiovascular risk. Current knowledge on the association between sclerostin and vascular diseases is summarized in this review.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 78 条
[1]   Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J].
Balemans, W ;
Ebeling, M ;
Patel, N ;
Van Hul, E ;
Olson, P ;
Dioszegi, M ;
Lacza, C ;
Wuyts, W ;
Van den Ende, J ;
Willems, P ;
Paes-Alves, AF ;
Hill, S ;
Bueno, M ;
Ramos, FJ ;
Tacconi, P ;
Dikkers, FG ;
Stratakis, C ;
Lindpaintner, K ;
Vickery, B ;
Foernzler, D ;
Van Hul, W .
HUMAN MOLECULAR GENETICS, 2001, 10 (05) :537-543
[2]   Wnt5a: A player in the pathogenesis of atherosclerosis and other inflammatory disorders [J].
Bhatt, Pooja M. ;
Malgor, Ramiro .
ATHEROSCLEROSIS, 2014, 237 (01) :155-162
[3]   The Wingless homolog, WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation [J].
Blumenthal, Antje ;
Ehlers, Stefan ;
Lauber, Jorg ;
Buer, Jan ;
Lange, Christoph ;
Goldmann, Torsten ;
Heine, Holger ;
Brandt, Ernst ;
Reiling, Norbert .
BLOOD, 2006, 108 (03) :965-973
[4]   Sclerostin Blood Levels Before and After Kidney Transplantation [J].
Bonani, Marco ;
Rodriguez, Daniel ;
Fehr, Thomas ;
Mohebbi, Nilufar ;
Brockmann, Jens ;
Blum, Markus ;
Graf, Nicole ;
Frey, Diana ;
Wuethrich, Rudolf P. .
KIDNEY & BLOOD PRESSURE RESEARCH, 2014, 39 (04) :230-239
[5]   Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages [J].
Borrell-Pages, Maria ;
Carolina Romero, July ;
Juan-Babot, Oriol ;
Badimon, Lina .
EUROPEAN HEART JOURNAL, 2011, 32 (22) :2841-2850
[6]   From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD [J].
Brandenburg, Vincent M. ;
D'Haese, Patrick ;
Deck, Annika ;
Mekahli, Djalila ;
Meijers, Bjorn ;
Neven, Ellen ;
Evenepoel, Pieter .
PEDIATRIC NEPHROLOGY, 2016, 31 (02) :195-206
[7]   Sclerostin levels in uremic patients: a link between bone and vascular disease [J].
Bruzzese, Annamaria ;
Lacquaniti, Antonio ;
Cernaro, Valeria ;
Ricciardi, Carlo Alberto ;
Loddo, Saverio ;
Romeo, Adolfo ;
Montalto, Gaetano ;
Costantino, Giuseppe ;
Torre, Francesco ;
Pettinato, Giuseppina ;
Salamone, Ignazio ;
Aloisi, Carmela ;
Santoro, Domenico ;
Buemi, Michele .
RENAL FAILURE, 2016, 38 (05) :759-764
[8]   Wnt antagonist sclerostin and Dickkopf-1 in gestational diabetes [J].
Catalano, A. ;
Pintaudi, B. ;
Morabito, N. ;
Giunta, L. ;
Loddo, S. ;
Corrado, F. ;
D' Anna, R. ;
Lasco, A. ;
Di Benedetto, A. .
DIABETES & METABOLISM, 2017, 43 (04) :375-377
[9]   Pulsed electromagnetic fields modulate bone metabolism via RANKL/OPG and Wnt/β-catenin pathways in women with postmenopausal osteoporosis: A pilot study [J].
Catalano, Antonino ;
Loddo, Saverio ;
Bellone, Federica ;
Pecora, Carmelo ;
Lasco, Antonino ;
Morabito, Nunziata .
BONE, 2018, 116 :42-46
[10]   Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus [J].
Catalano, Antonino ;
Pintaudi, Basilio ;
Morabito, Nancy ;
Di Vieste, Giacoma ;
Giunta, Loretta ;
Bruno, Maria Lucia ;
Cucinotta, Domenico ;
Lasco, Antonino ;
Di Benedetto, Antonino .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (03) :293-300